McIlrath & Eck’s XBiotech XBIT Stock Holding History

McIlrath & Eck’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.77K	Hold	753	–	–	﹤0.01%	1433
2025 Q4	$1.8K	Hold	753	–	–	﹤0.01%	901
2025 Q3	$2K	Hold	753	–	–	﹤0.01%	853
2025 Q2	$2.24K	Hold	753	–	–	﹤0.01%	828
2025 Q1	$2.44K	Hold	753	–	–	﹤0.01%	810
2024 Q4	$2.97K	Hold	753	–	–	﹤0.01%	832
2024 Q3	$5.82K	Hold	753	–	–	﹤0.01%	723
2024 Q2	$3.87K	Hold	753	–	–	﹤0.01%	758
2024 Q1	$6.12K	Hold	753	–	–	﹤0.01%	687
2023 Q4	$3.01K	Hold	753	–	–	﹤0.01%	769
2023 Q3	$3.1K	Hold	753	–	–	﹤0.01%	735
2023 Q2	$4.47K	Hold	753	–	–	﹤0.01%	694
2023 Q1	$2.6K	Hold	753	–	–	﹤0.01%	752
2022 Q4	$2.64K	Hold	753	–	–	﹤0.01%	723
2022 Q3	$3K	Hold	753	–	–	﹤0.01%	733
2022 Q2	$4K	Hold	753	–	–	﹤0.01%	671
2022 Q1	$7K	Hold	753	–	–	﹤0.01%	592
2021 Q4	$8K	Hold	753	–	–	﹤0.01%	573
2021 Q3	$10K	Hold	753	–	–	﹤0.01%	533
2021 Q2	$12K	Hold	753	–	–	﹤0.01%	501
2021 Q1	$13K	Buy	+753	New	+$14.1K	﹤0.01%	440

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McIlrath & Eck's XBIT Position: Q1 2026 in Review

McIlrath & Eck held its XBiotech (XBIT) position steady in Q1 2026 at 753 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

McIlrath & Eck first reported a position in XBIT in Q1 2021 and has held it in 21 quarters since. The position peaked at $13K in Q1 2021. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.

McIlrath & Eck held 753 shares of XBiotech worth $1.77K as of Q1 2026.
McIlrath & Eck left its XBiotech share count unchanged in Q1 2026.
XBiotech made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1433 holding.
McIlrath & Eck first reported a position in XBiotech in Q1 2021 and has held it in 21 quarters since.
McIlrath & Eck's XBiotech position peaked at $13K in Q1 2021.
37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.